Occult hepatitis B and infliximab-induced HBV reactivation [4]

Inflammatory Bowel Diseases

Volumn 13, Issue 4, 2007, Pages 508-509

  Madonia, Salvatore ^a   Orlando, Ambrogio ^a   Scimeca, Daniela ^a   Olivo, Mirko ^a   Rossi, Francesca ^a   Cottone, Mario ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CIPROFLOXACIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; METRONIDAZOLE; PREDNISONE; STEROID;

ADULT; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DNA SEQUENCE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LETTER; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT FAILURE; VIRUS REPLICATION;

ADULT; ANTIBODIES, MONOCLONAL; CARRIER STATE; CROHN DISEASE; FEMALE; HEPATITIS B; HUMANS; VIRUS ACTIVATION;

EID: 34247592817     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20035     Document Type: Letter

References (7)

1. Tillman HL, Wedemeyer H, Manns MP. Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplantation, fulminant hepatitis, hepatitis B virus reactivation. J Hepatol. 2003;39:S206-211.
2. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209-220.
3. Millonig G, Kern M, Ludwiczek, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol. 2006;4:974-976.
4. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004;53:1363-1365.
5. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomised controlled trials. JAMA. 2006;295:2275-2285.
6. Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003;37:1320-1328.
7. Marzano A, Angelucci P, Andreone P, et al. Focus on prophylaxis and therapy of hepatitis B in immuno-compromised patients. Available at: http://www.webaisf.org